Safety

Lupron Depot (leuprolide acetate) for depot suspension

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

June 2016

Summary View

PATIENT COUNSELING INFORMATION

Patients should be informed that:

  • LUPRON DEPOT is usually continued, often with additional medication, after the development of metastatic castration-resistant prostate cancer. (addition)

 

June 2014

Summary View

WARNINGS AND PRECAUTIONS
Effect on QT/QTc Interval

  • Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.

 

June 2011

Summary View

ADVERSE REACTIONS

Changes in Bone Density
  • Table 4 is revised to add the 95% confidence intervals (CIs) for the mean percent change from baseline in bone mineral density of lumbar spine in women treated with Lupron alone or Lupron plus norethindrone acetate. 
Postmarketing
  • minor editorial/formatting changes

 

Page Last Updated: 07/07/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.